Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical cyclophosphamide versus mometasone for mycosis fungoides
IRCT20140212016557N12Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of cyclophosphamide and mometasone in cutaneous T-cell lymphoma (CTCL) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Composite Assessment of Index Lesion Severity (CAILS). Started Dec 2023; status: completed.
02
Drugs
cyclophosphamidemometasone
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on IRCT20140212016557N12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140212016557N12.